- NEWS AND VIEWS
15 years after a giant leap for cancer genomics
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Nature 623, 920-921 (2023)
doi: https://doi.org/10.1038/d41586-023-03626-x
References
Ley, T. J. et al. Nature 456, 66–72 (2008).
Nowell, P. C. & Hungerford, D. A. Science 132, 1497 (1960).
Rowley, J. D. Nature 243, 290–293 (1973).
Druker, B. J. et al. Nature Med. 2, 561–566 (1996).
Druker, B. J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Samuels, Y. et al. Science 304, 554 (2004).
Lynch, T. J. et al. N. Engl. J. Med. 350, 2129–2139 (2004).
Paez, J. G. et al. Science 304, 1497–1500 (2004).
Miles, L. A. et al. Nature 587, 477–482 (2020).
Morita, K. et al. Nature Commun. 11, 5327 (2020).
Ding, L. et al. Nature 481, 506–510 (2012).
Wong, T. N. et al. Nature 518, 552–555 (2015).
Jongen-Lavrencic, M. et al. N. Engl. J. Med. 378, 1189–1199 (2018).
Klco, J. M. et al. JAMA 314, 811–822 (2015).
Mardis, E. R. et al. N. Engl. J. Med. 361, 1058–1066 (2009).
Parsons, D. W. et al. Science 321, 1807–1812 (2008).
Dang, L. et al. Nature 462, 739–744 (2009).
Mellinghoff, I. K. et al. N. Engl. J. Med. 389, 589–601 (2023).
Competing Interests
R.L.L is on the supervisory board of Qiagen and is a scientific adviser to Imago, Mission Bio, Kurome, Ajax, Auron, Prelude andC4 Therapeutics, each of which includes equity as compensation. He receives research support from Ajax, Zentalis and Abbvie. S.F.C. previously held equity interest in Imago Biosciences. None of these are related to the content of this paper. S.F.C. was a graduate student in the Ley laboratory from 2004 to 2009.